Diaceutics PLC Net Assets

Latest as of December 2025: GBX40.48 Million GBX ≈ $4.93K USD

Diaceutics PLC net assets. Based on the latest financial reports, Diaceutics PLC (DXRX) has net assets worth GBX40.48 Million GBX (≈ $4.93K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX50.01 Million ≈ $6.08K USD) and total liabilities (GBX9.53 Million ≈ $1.16K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore DXRX shareholders equity momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX40.48 Million
% of Total Assets 80.95%
Annual Growth Rate 73.18%
5-Year Change -0.42%
10-Year Change 3899.02%
Growth Volatility 228.8

Net Assets of Diaceutics PLC (2015–2025)

Net assets of Diaceutics PLC from 2015 to 2025. This chart illustrates how Diaceutics PLC's net assets have evolved over time, based on quarterly financial data. See DXRX equity to assets ratio to measure how much of total assets are equity-financed.

Annual Net Assets for Diaceutics PLC (2015–2025)

The table below shows the annual net assets of Diaceutics PLC from 2015 to 2025. For live market cap and overall valuation, see DXRX stock market capitalisation.

Year Net Assets Change
2025-12-31 GBX40.48 Million
≈ $4.93K		 +1.56%
2024-12-31 GBX39.86 Million
≈ $4.85K		 -2.28%
2023-12-31 GBX40.79 Million
≈ $4.96K		 -4.06%
2022-12-31 GBX42.51 Million
≈ $5.17K		 +4.59%
2021-12-31 GBX40.65 Million
≈ $4.95K		 +1.02%
2020-12-31 GBX40.24 Million
≈ $4.90K		 +99.87%
2019-12-31 GBX20.13 Million
≈ $2.45K		 +665.64%
2018-12-31 GBX2.63 Million
≈ $319.93		 +40.03%
2017-12-31 GBX1.88 Million
≈ $228.47		 +85.50%
2016-12-31 GBX1.01 Million
≈ $123.16		 +507.18%
2015-12-31 GBX166.71K
≈ $20.28		 --

Equity Component Analysis

This analysis shows how different components contribute to Diaceutics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 4164431200.0% over the analyzed period, indicating profitable operations and earnings retention.

Diaceutics PLC Net Assets Breakdown (December 2025)

Diaceutics PLC net assets breakdown by equity component as of December 2025.

Component Amount Percentage
Retained Earnings GBX41.60 Million 102.77%
Common Stock GBX170.00K 0.42%
Other Comprehensive Income GBX-980.00K -2.42%
Total Equity GBX40.48 Million 100.00%

Diaceutics PLC Competitors by Market Cap

The table below lists competitors of Diaceutics PLC ranked by their market capitalization.

Company Market Cap
Fonix Mobile plc
LSE:FNX
 $2.10 Million
Ragusa Minerals Ltd
AU:RAS
 $2.10 Million
Globavend Holdings Limited Ordinary Shares
NASDAQ:GVH
 $2.10 Million
Elevai Labs, Inc. Common Stock
NASDAQ:ELAB
 $2.10 Million
Centaurus Energy Inc
V:CTA
 $2.10 Million
Fortune Indonesia Tbk
JK:FORU
 $2.10 Million
MOBILUM TECHNOLOGIES INC.
F:C0B
 $2.10 Million
Surya Oil & Gas Corp.
NASDAQ:SURY
 $2.10 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Diaceutics PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 39,857,000 to 40,480,000, a change of 623,000 (1.6%).
  • Net income of 97,000 contributed positively to equity growth.
  • Other comprehensive income decreased equity by 354,000.
  • Other factors increased equity by 880,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income GBX97.00K +0.24%
Other Comprehensive Income GBX-354.00K -0.87%
Other Changes GBX880.00K +2.17%
Total Change GBX- 1.56%

Book Value vs Market Value Analysis

This analysis compares Diaceutics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 427.94x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 32933.62x to 427.94x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2015-12-31 GBX0.01 GBX203.50 x
2016-12-31 GBX0.01 GBX203.50 x
2017-12-31 GBX0.03 GBX203.50 x
2018-12-31 GBX0.04 GBX203.50 x
2019-12-31 GBX0.31 GBX203.50 x
2020-12-31 GBX0.52 GBX203.50 x
2021-12-31 GBX0.48 GBX203.50 x
2022-12-31 GBX0.49 GBX203.50 x
2023-12-31 GBX0.48 GBX203.50 x
2024-12-31 GBX0.47 GBX203.50 x
2025-12-31 GBX0.48 GBX203.50 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Diaceutics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.24%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.25%
  • • Asset Turnover: 0.77x
  • • Equity Multiplier: 1.24x
  • Recent ROE (0.24%) is below the historical average (6.23%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 -62.08% -7.40% 1.04x 8.05x GBX-120.16K
2016 73.81% 16.28% 1.33x 3.40x GBX645.91K
2017 35.32% 9.00% 1.34x 2.92x GBX475.42K
2018 24.05% 6.10% 1.33x 2.97x GBX369.36K
2019 1.98% 2.96% 0.60x 1.11x GBX-1.62 Million
2020 0.65% 2.07% 0.29x 1.08x GBX-3.76 Million
2021 1.38% 4.02% 0.31x 1.11x GBX-3.50 Million
2022 1.70% 3.71% 0.40x 1.14x GBX-3.53 Million
2023 -4.28% -7.37% 0.51x 1.14x GBX-5.82 Million
2024 -4.27% -5.30% 0.66x 1.22x GBX-5.69 Million
2025 0.24% 0.25% 0.77x 1.24x GBX-3.95 Million

Industry Comparison

This section compares Diaceutics PLC's net assets metrics with peer companies in the Health Information Services industry.

Industry Context

  • Industry: Health Information Services
  • Average net assets among peers: $2,187,566,071
  • Average return on equity (ROE) among peers: 0.31%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Diaceutics PLC (DXRX) GBX40.48 Million -62.08% 0.24x $2.10 Million
Cambridge Cognition Holdings Plc (COG) $2.99 Million -55.95% 2.77x $183.90K
Craneware Plc (CRW) $68.39 Million 24.62% 0.69x $4.53 Million
Feedback PLC (FDBK) $13.71 Million -15.45% 0.04x $25.32K
Induction Healthcare Group PLC (INHC) $-2.64 Million 0.00% 0.00x $111.33K
IQ-AI Ltd (IQAI) $16.49 Million 26.84% 0.40x $24.76K
Kooth plc (KOO) $10.85 Million -13.62% 0.24x $838.94K
Optima Health plc (OPT) $126.31 Million -0.19% 0.52x $3.28 Million
Renalytix AI plc (RENX) $17.26 Billion 36.25% 2.37x $289.79K

About Diaceutics PLC

LSE:DXRX UK Health Information Services
Market Cap
$2.10 Million
GBX17.27 Billion GBX
Market Cap Rank
#30003 Global
#680 in UK
Share Price
GBX203.50
Change (1 day)
+0.00%
52-Week Range
GBX126.50 - GBX204.50
All Time High
GBX204.50
Categories
Companies in UK Health Information Services Technology
About

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that en… Read more